About
Predicts cardiovascular and chronic-kidney-disease risk from retinal images; pursuing FDA De Novo. Targets a KOSDAQ listing in H1 2027.
HQ: Seoul, South Korea
Funding
₩20B (~$13.1M) Series C (Mar 2026); ₩51.2B (~$34M) total raised
—Company profile
Dr. Noon CVD (formerly Reti-CVD) — retinal-AI cardiovascular and kidney risk prediction, CE-approved and deployed in 170+ institutions.
Predicts cardiovascular and chronic-kidney-disease risk from retinal images; pursuing FDA De Novo. Targets a KOSDAQ listing in H1 2027.
HQ: Seoul, South Korea